Skip to main content

Atelvia FDA Approval History

FDA Approved: Yes (First approved October 8, 2010)
Brand name: Atelvia
Generic name: risedronate sodium
Dosage form: Delayed-Release Tablets
Company: AbbVie Inc.
Treatment for: Osteoporosis

Atelvia (risedronate sodium) is a bisphosphonate in a delayed-release formulation for treatment of postmenopausal osteoporosis.

Development timeline for Atelvia

DateArticle
Oct 11, 2010Approval Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.